FDA Declines to Issue Guidance on Alternative Funding Programs Importing Foreign Drugs

The Food and Drug Administration (FDA) has declined to issue specific guidance on alternative funding programs (AFPs) that import prescription drugs from foreign markets. AFPs connect patients whose health plans do not cover expensive medications for critical diseases with more affordable versions obtained overseas.

U.S. regulators state that these imports violate import laws. In a letter dated March 27, 2024, the FDA responded to a citizen petition filed by Aimed Alliance, a non-profit health policy organization, in March 2024. The petition requested a definitive position on AFPs and the use of international importation to reduce drug costs.

It specifically sought a guidance document to clarify the agency's policy on AFPs importing drugs from overseas. The FDA acknowledged concerns raised by Aimed Alliance and noted that drugs circumventing regulatory safeguards may be contaminated, counterfeit, or contain varying amounts of active ingredients.

However, the agency denied the request for a clear position statement and specific guidance, stating that it was not warranted at this time. The letter indicated that issuing such guidance would not be an efficient use of the FDA's limited resources.

>"We take complaints seriously and appreciate the information that you have provided. " >— FDA letter, signed by Michael Davis, deputy director for the FDA's Center for Drug Evaluation and Research (Cnbc) The FDA's response stated that enforcement actions fall outside the scope of citizen petition procedures.

Aimed Alliance is among several patient advocacy groups that have requested the FDA to address AFPs using foreign sources for medication imports. Aimed Alliance did not immediately respond to a request for comment.

A CNBC investigation in November revealed the presence of AFPs across the United States. These programs enable patients to obtain critical drugs for little or no cost, according to operators. A Homeland Security Investigations official stated during the investigation that AFP practices are illegal.

The proliferation of AFPs occurs amid ongoing debates over drug affordability in the U.S. Patients with critical diseases, such as those requiring expensive treatments, are often affected when health plans do not provide coverage. Foreign imports offer lower costs but raise concerns about safety and compliance with U.S. regulations.

The FDA's decision leaves existing laws on foreign drug importation without additional clarification, potentially maintaining uncertainty for AFPs and patients. Regulators continue to monitor imports, and complaints can be submitted through established channels.

Patient advocacy groups may pursue further actions, such as additional petitions or legal challenges, to address the issue. The stakes involve access to affordable medications balanced against risks of unregulated drugs entering the U.S. market.